Image-derived input function in dynamic human PET/CT: methodology and validation with 11C-acetate and 18F-fluorothioheptadecanoic acid in muscle and 18F-fluorodeoxyglucose in brain by Etienne Croteau et al.
ORIGINAL ARTICLE
Image-derived input function in dynamic human PET/CT:
methodology and validation with 11C-acetate
and 18F-fluorothioheptadecanoic acid in muscle
and 18F-fluorodeoxyglucose in brain
Etienne Croteau & Éric Lavallée & Sébastien M. Labbe & Laurent Hubert &
Fabien Pifferi & Jacques A. Rousseau & Stephen C. Cunnane & André C. Carpentier &
Roger Lecomte & François Bénard
Received: 25 November 2009 /Accepted: 8 March 2010 /Published online: 2 May 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose Despite current advances in PET/CT systems, blood
sampling still remains the standard method to obtain the
radiotracer input function for tracer kinetic modelling. The
purpose of this study was to validate the use of image-derived
input functions (IDIF) of the carotid and femoral arteries to
measure the arterial input function (AIF) in PET imaging. The
data were obtained from two different research studies, one
using 18F-FDG for brain imaging and the other using 11C-
acetate and 18F-fluoro-6-thioheptadecanoic acid (18F-FTHA)
in femoral muscles.
Methods The method was validated with two phantom
systems. First, a static phantom consisting of syringes of
different diameters containing radioactivity was used to
determine the recovery coefficient (RC) and spill-in factors.
Second, a dynamic phantom built to model bolus injection and
clearance of tracers was used to establish the correlation
between blood sampling, AIF and IDIF. The RC was then
applied to the femoral artery data from PET imaging studies
with 11C-acetate and 18F-FTHA and to carotid artery data
from brain imaging with 18F-FDG. These IDIF data were
then compared to actual AIFs from patients.
Results With 11C-acetate, the perfusion index in the femoral
muscle was 0.34±0.18 min−1 when estimated from the
actual time–activity blood curve, 0.29±0.15 min−1 when
estimated from the corrected IDIF, and 0.66±0.41 min−1
when the IDIF data were not corrected for RC. A one-way
repeated measures (ANOVA) and Tukey’s test showed a
statistically significant difference for the IDIF not corrected
for RC (p<0.0001). With 18F-FTHA there was a strong
correlation between Patlak slopes, the plasma to tissue
transfer rate calculated using the true plasma radioactivity
content and the corrected IDIF for the femoral muscles
(vastus lateralis r=0.86, p=0.027; biceps femoris r=0.90,
p=0.017). On the other hand, there was no correlation
between the values derived using the AIF and those derived
using the uncorrected IDIF. Finally, in the brain imaging
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study with 18F-FDG, the cerebral metabolic rate of glucose
(CMRglc) measured using the uncorrected IDIF was
consistently overestimated. The CMRglc obtained using
blood sampling was 13.1±3.9 mg/100 g per minute and
14.0±5.7 mg/100 g per minute using the corrected IDIF
(r2=0.90).
Conclusion Correctly obtained, carotid and femoral artery
IDIFs can be used as a substitute for AIFs to perform tracer
kinetic modelling in skeletal femoral muscles and brain
analyses.
Keywords Positron emission tomography .
Tracer kinetic modelling . Image-derived input function
Abbreviation
AIF Arterial input function
CMRglc Cerebral metabolic rate of glucose
FDG Fluorodeoxyglucose
FTHA Fluorothioheptadecanoic acid
IDIF Image-derived input function
PVE Partial volume effect
RC Recovery coefficient
ROI Region of interest
TAC Time–activity curve
Introduction
PET is an important tool to probe in vivo biochemistry and
metabolism for cardiac, brain and cancer imaging [1]. This
has prompted the development of several new radiotracers
and imaging techniques, including tracer kinetic modelling
methods to quantify various physiological or biochemical
parameters [2–4]. While diagnostic studies in oncology
commonly use the semiquantitative standardized uptake
value, a single static measurement [5, 6], metabolic research
questions generally require more complex tracer kinetic
modelling approaches or graphical analysis [1, 7, 8]. Tracer
kinetics can be used to model specific physiological or
biochemical parameters and to decouple the various factors
involved in tracer influx and efflux from a tissue [5, 9–12].
The most common kinetic models are compartmental
kinetic models [5, 13] and graphical analysis methods such
as the Patlak plot, also called the Gjedde-Patlak and Patlak-
Rutland plot [1, 14]. Both approaches require an accurate
estimation of the arterial input function (AIF), for which
multiple samples of arterial blood or arterialized venous blood
are needed [15, 16]. Arterial access can be problematic in
some patients and has a low but still significant risk of
complications [8, 9]. Venous access in the hand to obtain
arterialized venous blood can be difficult and it is not always
possible to maintain consistent sampling, timing and volume
across experiments. Multiple blood sampling requires addi-
tional staff and may be more difficult in the clinical setting or
in large-scale studies.
Alternatives to multiple blood sampling exist, including
general population standard curves [17] or reduction of the
number of blood samples [4, 8]. Indeed, in some situations,
only one blood sample may be sufficient [9]. A reference
tissue region of interest (ROI) such as muscle can
sometimes be used to eliminate the need for an AIF [18],
but in many cases such an ROI may not be available.
Factorial analysis which targets well-defined parameters to
which the proper kinetic function is attributed has also been
used [3].
Accurate image-derived input functions (IDIF) obtained
from dynamic images would greatly simplify tracer kinetic
modelling or graphical methods in quantitative clinical PET
studies. Since large arteries are often in the same field of
view as the target organ of interest, in principle, the AIF
can be obtained directly from imaging data, much as is
done in cardiac imaging using the myocardial cavity [2].
Indeed, the use of carotid arteries to obtain the IDIF for
brain studies has already been explored by several groups
[8, 19–23] showing that with proper correction for partial
volume effect (PVE), IDIF can be a suitable alternative to
AIF.
Hence, the purpose of the present study was to
thoroughly validate the use of the IDIF and calculate
suitable factors for PVE correction of an artery’s diameter.
This was done using two different phantoms to mimic
blood vessels of various sizes and to model the AIF. Our
human data came from studies performed on two different
scanners, a Gemini GXL scanner [24] and a Gemini TF
“time of flight” PET/CT scanner [25], so the validation was
done for both scanners taking into account the properties of
each and the nature of the radioisotopes. We then applied
the derived correction factors to two human PET/CT studies




Two different phantoms were used to develop our IDIF
method, one to validate the measurement of radioactivity as
a function of arterial diameter, including PVE and spill-in
effect, and the other to simulate the kinetics of a bolus
tracer injection into the arterial system. The first phantom
consisted of six syringes ranging in diameter from 4.7 to
29 mm (1 to 60 cm3). These syringes were immersed in a
Plexiglas cylinder (diameter 19.9 cm, length 30 cm) filled
with water to represent the attenuation and scattering
environment of the patient. Artery size and IDIF phantom
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studies were repeated for both the Philips Gemini GXL
scanner and the Philips Gemini TF scanner with [11C] and
[18F] at a concentration of 0.07±0.03 MBq/ml using the
same acquisition parameters as for the human studies (see
below). The spill-in factors were calculated using cold
syringes immersed in a radioactive water cylinder ranging
between 6.0 and 1.0 kBq/ml for the representation of
muscle radioactivity contamination.
The first aim of the static phantom study was to
determine the recovery correction factors as a function of
object diameter for each scanner [26] (Fig. 1). Briefly, once
the images were reconstructed, three ROIs were drawn on
each syringe in the transaxial planes, and then for each ROI
the maximum value of the four highest adjacent pixels was
recorded and fitted to Eq. 1 to obtain the recovery
coefficient (RC) as a function of object diameter x (Fig. 1a).
RCðxÞ ¼ a  x dð Þ= 1þ x dð Þ=bð Þcð Þ1=c ð1Þ
The parameters a and d in Eq. 1 represent, respectively,
the slope of the curve and the lower limit of the object’s
diameter which may be corrected adequately. The artery
dimensions obtained from CT images were the same as the
object dimensions. Therefore the value could be directly used.
However, the relationship between the full-width at half-
maximum (FWHM) of the object measured on the PET images
and the actual size of the target (syringe diameter) was
evaluated using a second-order polynomial fit (quadratic
equation) (Fig. 2):
f ðxÞ ¼ B0 þ B1xþ B2x2 ð2Þ
The second aim was to accurately determining the spill-
in correction factor as a function of object diameter
(Fig. 1b). Contamination from outside the syringe repre-
sents spill-in at an exponential rate into the lumen as a
function of the diameter. ROIs were drawn on the transaxial
plane of each syringe and the average results were fitted to
Eq. 3 for the spill-in factor of the object diameter (Fig. 1b).
Spill  inðxÞ ¼ 1 Plateauð Þ  e k»xð Þ þ Plateau ð3Þ
The monoexponential equation is described with k, a
constant equal to the reciprocal of the spill-in range, the
object diameter x, and Plateau corresponding to the
asymptotic spill-in contribution to very large objects.
Most of the phantoms used to image arteries have a
diameter of 6.35 mm to simulate a carotid artery and 6.35 mm
or 7.94mm for a superficial femoral artery [27]. In the present
study, we used a diameter of 6.35 mm to represent the
diameters of both the carotid and femoral arteries. This was
based on reported values measured by CT, Doppler,
pathological examination and MRI, in which the diameter
of these arteries ranged from 4.4 to 12 mm, with a mean
diameter of 7 mm [27–30]. It is, however, important to keep
Fig. 1 The static arterial phantom was used to obtain the recovery
factors for cylindrical objects (syringes) ranging in diameter from 4 to
29 mm (a) and equations to calculate the spill-in ratio (b). a The
phantom was imaged on the Philips Gemini TF PET/CT scanner with
18F (dashed line, diamonds) and on the Gemini GXL PET/CT scanner
with 11C (solid line, triangles) and with 18F (dotted line, circles).
These data were then fitted using Eq. 1, and the fits are represented by
the curves. b Symbols represent a series of activities and the
exponential fit to the data
Fig. 2 Correlation between FWHM measured in the PET images using
an activity profile across the centre of the syringes and the actual diameter
of the static arterial phantom syringes. Lines represent the fits: for the 18F-
FDG brain imaging protocol with 2-mm voxels on the Gemini TF PET/
CT scanner (dotted line, circles), and for 11C-acetate (solid line, squares)
and 18F-FTHA with a whole-body protocol and 4-mm voxels on the
Gemini GXL PET/CT scanner (dashed line, crosses)
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in mind that artery diameter varies from person to person
according to factors such as age, sex, and weight [31].
For our three imaging protocols, we set blood flow in the
dynamic phantom to 200 ml/min for both the femoral and
the carotid arteries. This rate compares well with the actual
flow rate reported for the superficial femoral artery (196±
65 ml/min) [32] and carotid artery (251±51 ml/min) [33].
This was done with a phantom designed to simulate arterial
blood flow in muscle. The phantom consisted of Tygon
tubing immersed in a water bath representing the muscle
surrounding the artery. One end of the tube was attached to
a reservoir that was used to introduce and modulate the
concentration of radiotracer. Blood circulation was simulated
by pumping water at a constant rate of 200 ml/min through the
field of view of the PET scanner. To model blood flow
following bolus injection, we started with an initial volume of
400 ml of water in the reservoir and then poured 200 ml of
radiotracer solution into the reservoir over a period of 1 min.
Water was then added to the reservoir at a rate of 400 ml/min
to represent the blood clearance of the radiotracer. Samples
were taken from the reservoir at 20 s, 40 s, 60 s, 2 min, 3 min,
5 min and 10 min to simulate blood sampling in patients, and
their radioactivity was measured in a gamma counter (Cobra).
Since this is considered to be equivalent to performing blood
sampling in a patient, it was our gold standard for phantom
measurements (Fig. 3a).
The radioactivity in the simulated blood samples taken
from the reservoir was expressed in kBq/ml and was
correlated with the IDIF derived from PET imaging of the
dynamic phantom after proper correction for RCs. Three
transaxial ROIs were drawn on adjacent axial planes and
the maximum value of the four highest adjacent pixels was
recorded. The maximum concentration of radiotracer in the
carotid phantom (20–40 kBq/ml) was similar to that
administered to subjects during our clinical studies. In
order to establish the reliability of the FWHM correction
method under different conditions, the arterial injection
modelling experiments were repeated three times for each
protocol.
Human studies
The data for the present analysis came from two different
clinical research projects that took place in our PET facility.
One was a dynamic analysis of femoral muscle metabolism
in diabetic patients and the other was an evaluation of brain
glucose metabolism in young and elderly subjects. In the
first study, six healthy volunteers, all men aged 37±
13 years, were imaged first with 185 MBq of 11C-acetate
for 30 min in dynamic list mode and then with 185 MBq of
the fatty acid analogue 18F-FTHA for another 50 min, again
using dynamic list mode acquisition. This study was done
on a Philips Gemini GXL PET scanner using a row action
Fig. 3 Time–activity curves of input functions from withdrawn blood
samples and the IDIF with the appropriate correction. a Dynamic
artery phantom designed to model radiotracer influx and blood
clearance. The phantom was made from Tygon tubing, 6.35 mm
diameter, entering the PET scanner field of view and attached to a
water reservoir used to introduce the radiotracer into the system.
Samples taken from the phantom (solid circles) were used as reference
and were compared to data obtained from uncorrected IDIF (dashed
line) and the IDIF-corrected for partial volume using the
corresponding diameter estimated from the FWHM (solid line). b, c
Examples of input function for a 18F-FDG brain study and for a 18F-
FTHA muscle study (solid circles blood samples, dashed line IDIF not
corrected. solid line IDIF corrected)
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maximum likelihood algorithm (RAMLA) without sinogram
rebinning for reconstructing images and a time sequence of
12×15 s, 8×30 s, and 3×60 s, with the remaining acquisitions
being reconstructed with 5-min time frames. The other
parameters were as follows: isotropic voxel size 4 mm, and
60-cm diameter by 18-cm axial field of view. All IDIF and the
FWHM were drawn on both the left and right arteries over
three consecutive planes, with 4 cm between planes. The
maximum value of the four highest adjacent pixels for each
frame were recorded.
In the second study, the cerebral metabolic rate of
glucose (CMRglc) was measured with 18F-FDG in six
healthy volunteers, five men and one woman aged 59±
23 years. These scans were performed on a Philips Gemini
TF scanner using list mode, with time-of-flight enabled,
with the same time frames and parameters as the first study
except for the image reconstruction algorithm (line-of-
response row action maximum likelihood algorithm) and
the size of the isotropic voxel which was 2 mm. For the
carotid arteries, the ROIs were drawn from the PET/CT
coregistration images. For each artery, three adjacent planes
were selected below the skull, their x and y diameter was
then measured from the CT images and the maximum value
of the four highest adjacent pixels for each plane was
recorded. Serial blood sampling was done in both studies
following the same time points as the dynamic sequence
(12×15 s, 8×30 s, 3×60 s, and all subsequent samples
withdrawn every 5 min). The arterialized venous blood was
withdrawn with retrograde insertion of a cannula into a
dorsal arm or a distal forearm vein. The limb was kept warm
with a heating blanket.
PET data analysis
In the first study, the muscle perfusion index K1 (min
−1)
was estimated from 11C-acetate using a three-compartment
model [11, 34]:
CtðtÞ ¼ A1  exp  k2 þ k3ð Þtð Þ þ A2  exp k4tð Þ½   CpðtÞ
þ v:CtotðtÞ
ð4Þ
A1 ¼ K1k2= k2 þ k3ð Þ
A2 ¼ K1k3= k2 þ k3ð Þ
In Eq. 4, Ct, Cp and Ctot represent as a function of time
the tracer concentration in tissue, plasma and the total
arterial blood, respectively. K1 to k4 are the rate constants
and v represents the blood volume. In this equation, K1
represents blood flow, while k2 is an index of myocardial
oxygen consumption.
The contribution of 11C-acetate metabolites to the radio-
activity measured in the plasma was estimated as follows:
CpðtÞ ¼ 1 ao  1 exp t  log 2=mð Þð Þ½   CtotðtÞ ð5Þ
In Eq. 5, the variables ao and m are the parameters to be
fitted.
For the 18F-FTHA data, in order to compare the IDIF
obtained from the ROIs with those obtained from the actual
plasma samples taken from the subjects (Fig. 5), we
corrected first for the PVE (Eq. 1) corresponding to the
artery diameter estimated from the FWHM of the radioac-
tivity profile. After that, a second correction was applied for
the spill-in of radioactivity from muscle into the artery
lumen in the late portion of the time–activity curve (TAC).
This was done again with the corresponding factor for the
diameter observed (Fig. 1b), multiplied by each point of
the muscle activity and subtracted from the TAC where the
activity of the muscle in the late portion was higher or equal
to the artery lumen (Fig. 3b). This approach of spill-in
correction was compared with another technique in which a
blood sample is needed. This was done by subtracting the
value of the last point of the ROI TAC from the
corresponding blood sample radioactivity, thereby obtain-
ing the amount of unwanted radioactivity coming from
muscle tissue. This value was then divided by the muscle
radioactivity content estimated from the PET image, with
the resulting fractional factor then being used to correct the
late portion of the TAC [35]. Both approaches yielded
similar results (r2=0.99 Fig. 5d). Lastly, the data were
corrected for the presence of 18F-FTHA metabolites in the
blood. To comply with our kinetic model, the quantitative
(kBq/ml) values were obtained for whole blood and
converted to plasma values using a constant factor derived
from the subject’s blood samples. With these corrections,
the plasma to tissue transfer rate, Ki, was obtained using a
Patlak graphical analysis for irreversible ligands (Eq. 6)
[14, 36]:
Ki ¼ K1  k3k2 þ k3 ð6Þ
The transfer of the tracer from plasma to the irreversible





CpðtÞ þ Vd ð7Þ
Because Eq. 7 is linear at equilibrium (5–35 min) [37],
the fractional uptake constant (Ki) can be derived directly
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from the slope of the curve of Ct(T)/Cp(T) against Cp(T)
divided by the integral of the plasma TAC-Cp(T).
In the second study, we used the classical three-compartment
model (Eq. 8) to estimate CMRglc as originally described by
Sokoloff et al. [37], a method which has been validated for
18F-FDG studies in the human brain [13].
CMRglc ¼ Cp
LC
 K1  k2
k2 þ k3 ð8Þ
where CMRglc is in milligrams per 100 g per minute, Cp is
the plasma glucose concentration, LC is a lumped constant
(0.52) [38], k1 and k2 are the rate constants for carrier-
mediated transport of 18F-FDG between plasma and tissue and
k3 is the phosphorylation rate constant of
18F-FDG at steady-
state. The IDIF were only corrected for the partial volume.
Correction for spill-in was not necessary as the carotid ROIs are
located outside of the skull where they are not contaminated by
radioactivity from the brain [23]. We used a large ROI, for the
brain tissue, traced on the frontal lobe of the brain without
using a morphological atlas to estimate CMRglc.
Statistical analysis
All data were expressed as means±SD. Pearson correlation
coefficients (r) and the determination coefficients (r 2) were
used to evaluate the strength of the relationship between the
diameter of the arterial phantom syringes, the FWHM
obtained by PET and artery dimensions obtained by CT. For
the human studies, the Pearson correlation and determination
coefficients were used to assess the relationship between the
IDIF, spill-in factor correction, Tygon tubing size, measure-
ments obtained from the subjects and phantom blood
clearance curves. For the brain study, arterial dimension and
FWHM from the PET activity profiles were compared using a
paired t-test. One-way repeated measures (ANOVA) with
Tukey’s test was used to assess the differences between the
blood sampling data, the IDIF not corrected for PVEs and
the IDIF corrected for PVEs in the clinical studies. All p
values smaller or equal to 0.05 were considered statistically
significant.
Results
The RC curves for each type of study and scanner from the
phantom measurements are shown in Fig. 1. To define our
correction domain, we set the upper limit for the RC at
90%, while the lower limit below which the correction is a
constant factor, was set by the value of d in Eq. 1. We also
measured the relationship between the FWHM obtained
from PET images and the true diameter of the targets. This
relationship between the PET-derived FWHM and actual
phantom syringe size was needed, since without contrast
agents it was not possible to reliably measure the diameter
of the superficial femoral artery directly using the CT
images from the PET/CT scanner in this study. Fitting the
data from the phantom to a second-order polynomial
equation showed a highly significant correlation (r2>0.98)
between the PET-measured FWHM and the real diameter of
the simulated arteries. With a regression curve, the standard
deviation of the residuals (Sxy) was 0.9 mm for
11C-acetate,
0.6 mm for 18F-FTHA and 0.5 mm for 18F-FDG (Fig. 2).
Further validation of the second-order polynomial
equation fitted model was obtained from the 6.35-mm
inner diameter tube of the dynamic femoral phantom. All
validations were done in triplicate for each scanner and
study condition (Table 1). 11C-Acetate overestimated the
size of the target (6.35 mm tubing) by 6±2%, while
underestimation with 18F-FTHA was less (3±2%). For the
brain study with 18F-FDG on the Gemini TF, the carotid
artery diameter was slightly overestimated (4±7%) and the
data were more variable.
For the brain study, the diameter of the left and right
median carotid arteries was estimated from the PET image
following a 18F-FDG bolus injection. From the coregistered
PET/CT image, it was also possible to locate the arteries on
the CT image and measure their diameter. The measured
values were not significantly different: 7.3±0.6 mm by PET
and 7.9±0.5 mm by CT (paired Student's t-test; p=0.08).
Consequently, there were no significant differences between
the RCs extracted using the PET or the CT images (0.54±0.04
vs. 0.58±0.03; p=0.24). Thus there was a nonsignificant
difference between the values of CMRglc (14.0±5.7 vs 13.4±
5.6; p=0.18) obtained using the two artery size measurement
methods.
The dynamic femoral phantom was designed to simulate
the influx and subsequent clearance of a bolus injection of
radiotracer in an artery (Fig. 3a), as well as to model the
blood clearance curve. Here also, all measurements were
performed in triplicate for each protocol. The radioactivity
data obtained from sampling the radioactive solution in the
phantom reservoir were first converted into kBq/ml and
then correlated with the phantom PET data, corrected for
the PVE using RCs corresponding to the tube inner
diameter of 6.35 mm. The following coefficients of
determination (r2) were obtained: Gemini GXL with
whole-body protocol for 11C-acetate and 18F-FTHA
r2=0.94 and 0.99, respectively, and Gemini TF with brain
study protocol for 18F-FDG r2=0.98.
The correction methods developed with the phantoms were
then applied to actual human subject data. With 11C-acetate,
the perfusion index, K1 (min
−1), was obtained independently
for both the vastus lateralis and the biceps femoris muscles
using a three-compartment model (Fig. 4). The perfusion
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index for both muscles was not significantly different when
estimated from the blood TAC (0.34±0.18 min−1) compared
to the corrected IDIF (0.29±0.15 min−1). However, the
uncorrected IDIF gave perfusion index values of 0.66±
0.41 min−1 that were significantly overestimated compared
to those obtained from the blood TAC or with the corrected
IDIF repeated measures ANOVA (p<0.0001).
For the 18F-FTHA study, the muscle (vastus lateralis,
biceps femoris) to plasma transfer rate constant (Ki) was
computed from a Patlak graphical analysis (Fig. 5), yielding
the following values: AIF from the plasma samples
(Ki=0.076±0.035 min
−1), IDIF corrected for the PVE and
the spillover from the muscle (Ki=0.074±0.031 min
−1) and
uncorrected IDIF (Ki=0.102±0.044 min
−1). There was a
significant positive correlation (r=0.86, p=0.027, for vastus
lateralis; r=0.89, p=0.017, for biceps femoris) between the
slopes of the corrected data and the actual plasma
radioactivity AIF. However, there was no correlation
(r=0.04 for vastus lateralis, and r=0.002 for biceps femoris)
between the slopes of the Patlak curves derived from the
AIF and the uncorrected IDIF.
In the 18F-FDG brain imaging study, a standard
compartmental analysis was applied using the frontal brain
region for the tissue, and the blood curve was obtained
using blood samples, the uncorrected IDIF and the IDIF
corrected for PVE (Fig. 6). For blood samples, IDIF
without correction and the IDIF corrected for PVE the K1
values were 0.029±0.011 min−1, 0.076±0.014 min−1 and
0.039±0.007 min−1, respectively. The average CMRglc
values for the frontal brain were obtained from each input
function: blood samples 13.8±3.9 mg/100 g per minute,
IDIF without correction 24.8±8.8 mg/100 g per minute and
IDIF corrected for PVE 14.0±5.7 mg/100 g per minute.
Thus, omitting the correction for PVE resulted in an
overestimation of the CMRglc by a factor of approximately
two. One-way ANOVA repeated measures and Tukey’s test
showed significant differences for K1 and CMRglc only for
the IDIF uncorrected for PVE (F(2,5)=48.37; p<0.0001)
and (F(2,5)=36.42; p<0.0001).
In order to establish the robustness of the correction
when applied to human studies, we assessed the impact of
corrections for PVEs assuming differences of ±1 mm
between the real and measured artery sizes. For the 11C-
acetate muscle study, underestimating the femoral artery size
by 1 mm resulted in an underestimation of the perfusion index
by 67±6%; if the size was overestimated by 1 mm, the
perfusion index was overestimated by 66±9%. A similar but
less important effect was observed with 18F-FTHA where the
effect on the Ki for a 1-mm underestimation and overesti-
mation was −13±6% and +12±6%, respectively. Although a
±1-mm error is unlikely with the CT modality because of its
excellent spatial resolution, we were nonetheless interested in
computing the effect of such a deviation on the estimation of
CMRglc by CT. It was found that an underestimation of the
diameter of the carotid artery by 1 mm would decrease
CMRglc by 17±6% whereas an overestimation by 1 mm
would increase it by 10±3%.
Discussion
We report here two specific developments: (1) methods for
PVE correction appropriate for the PET camera, isotopes,
acquisition protocols and kinetic reconstruction, and (2) an
excellent correlation between AIF and IDIF obtained in the
same subjects, based on the results of experiments
conducted using a static phantom to measure RCs for
blood vessels of various sizes and a dynamic phantom
aimed at modelling the AIF. We already know that kinetic
analysis yields important information that cannot be
obtained from static images. In cardiac imaging, for
example, kinetic analysis of 11C-acetate PET data is useful
to measure myocardial perfusion and oxygen consumption
[39, 40]. Similarly, CMRglc can only be obtained using
tracer kinetic analysis [8]. One of the main limitations of
kinetic analyses is the necessity to draw serial arterial or
arterialized blood samples to obtain the blood input function
required by the mathematical models [1]. Other strategies
Table 1 Recovery coefficients and the corresponding diameters (means±SD) estimated from the FWHM measured in the PET images
Radiotracer Diameter (mm) Recovery coefficient r2 valuec
18F-FDG (Gemini TF) Human carotida 7.93±0.46 0.58±0.02
Phantomb 6.65±0.44 0.49±0.03 0.975
11C-acetate (Gemini GXL) Human femoral arterya 9.63±0.78 0.52±0.08
Phantomb 6.77±0.12 0.28±0.01 0.940
18F-FTHA (Gemini GXL) Human femoral arterya 9.48±1.21 0.49±0.09
Phantomb 6.21±0.13 0.25±0.01 0.990
a Human studies (n=6).
b Dynamic phantom (tube diameter 6.35 mm) (n=3).
c Correlation of the IDIF with the radioactivity of the samples from the phantom reservoir.
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exist to bypass this requirement [8, 19–23], but the use of an
IDIF is attractive for several reasons. First, it eliminates a
common source of error – the need for precise cross-
calibration between a dose calibrator and the PET scanner.
Second, by providing the equivalent of an AIF without blood
sampling during the acquisition, IDIF makes the study
simpler, with reduced risk and discomfort for the subject,
fewer manipulations, reduced personnel requirements, and
lower risk of occupational hazards related to blood handling.
Third, serial blood sampling can also be a deterrent to
subject participation when venous or arterial access is
problematic, i.e. in cancer patients or in the elderly.
Despite its intrinsic utility, IDIF has some limitations.
The first is the need to correct for PVEs. Because of the
difficulty in obtaining reliable data from arterial imaging,
IDIF was for a long time restricted to the left ventricle,
which offers a relatively large pool of arterial blood in
myocardial imaging studies [36]. Now that most human
PET/CTscanners can achieve a spatial resolution <5mm, IDIF
analysis can be considered for large blood vessels such as the
femoral or the carotid arteries [23]. Accurate determination of
the diameter of large arteries by PET/CT allows the
computation of reliable recovery factors, making it possible
to obtain the equivalent of AIFs directly from the ROIs traced
on the PET/CT images of these arteries. The availability of
more sensitive scanners and the feasibility of using list mode
along with better reconstruction algorithms have also
contributed to the improvement in spatial and time resolution,
and thus to the quality of radiotracer kinetic analysis.
PVE is also a key challenge in obtaining an accurate IDIF.
In 1984, Kessler et al. [41] were among the first to propose a
correction scheme for PVE which took into account the
impact of the physical characteristics of the scanner. In the
present study, emphasis was placed on the reconstructed
image, since the scanner characteristics, the nature of the
radiotracer and blood vessel diameter are implicitly present
in the data derived from the image. Accordingly, the
mathematical expressions we used to correct for PVE were
directly derived from the images obtained in each study,
making it easier to integrate the scanner characteristics while
computing the recovery factors.
When dealing with recovery factors, the behaviour of
cylindrical objects such as arteries is quite different from
that of spherical objects, since shape has an effect on voxel
overlap [42]. Thus, a cylindrical phantom was selected
instead of the usual spherical ones to properly simulate
blood vessel geometry. In this study, phantom measurements
confirmed that the combination of CT and PET images within
the same investigation can improve the measurement of target
size and spatial position compared to conventional PET
without CT.
Once the proper artery diameter was established, the data
from the dynamic PET acquisition were validated against
the water reservoir samples. Each protocol was evaluated,
since 11C has a longer positron range than 18F, and we
believe this explains why the size estimate was less precise
with this isotope. The FDG study was performed using a
different scanner (Gemini TF instead of Gemini GXL), with
a higher spatial resolution and smaller voxels for the brain
acquisition protocol. This explains why the size estimate
was more precise with 18F-FDG than with 18F-FTHA.
Fig. 4 a, b 11C-acetate perfusion index, K1, for the vastus lateralis (a)
and biceps femoris (b) obtained by kinetic analysis with a three-
compartment model. For each muscle, the average and range of K1
values were obtained from an AIF derived by blood sampling (Blood),
IDIF and corrected for PVE (IDIFcor). c The K1 values obtained from
blood sampling are also correlated with the corrected IDIF values. The
data from each subject are identified by the same symbol across all
conditions
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Blood sampling is widely considered to be the gold
standard for AIF, but blood samples are almost exclusively
taken from the extremity of the upper limbs. This means
that the sampling site is often quite remote from the target
organ, requiring the assumption that the blood tracer
concentration within the arterial network is homogeneous.
However, when the AIF is obtained by IDIF, a blood vessel
close to the target organ can be selected, which is more
representative of the true tracer input to the target organ.
Nevertheless, the IDIF obtained from PET data represents
whole blood activity and a partition coefficient must be
assumed to provide the plasma input function. There is now,
however, a tendency to prefer whole blood to calculate the
AIF, as this makes the experiment simpler and also yields
reliable results [43]. Since the clinical studies were at the
pilot stage, our analysis was not powered to detect
substantial differences between the various blood analysis
methods. The fact that we did detect a substantial difference
between the uncorrected IDIF and the blood samples shows
that proper correction methods must be applied to the image-
derived AIF. While we observed a good general agreement
between the values provided by corrected IDIF and blood
samples, further studies are needed on larger datasets to
properly document the error of the estimate provided by the
use of a corrected IDIF compared to blood samples.
The kinetic model used for our 11C-acetate PET
measurements of heart oxygen consumption already has
IDIF built into the study design in which the AIF came
from ROIs traced on the left ventricular cavity. In this
model, a whole-blood input function is used instead of
plasma sampling [26, 40]. For 11C-acetate kinetics with
high blood flow rates, it may be appropriate to use a first
pass extraction model [44], but considering that we were
concerned with validating AIFs from ROIs traced on leg
arteries at rest which have a low perfusion rate, our current
model was assumed to be appropriate. Measurements
Fig. 5 a, b Slope of the plasma to tissue transfer rate, Ki (min
−1), of
18F−FTHA for the vastus lateralis (a) and biceps femoris (b) obtained
by Patlak graphical analysis. For each muscle, the average and range
of Ki was obtained from an AIF derived from blood sampling
(Plasma), uncorrected IDIF and corrected for PVE and spillover (IDIF
cor). The data from each patient are identified by the same symbol
across all conditions. c The Ki values obtained from blood sampling
are correlated with the corrected IDIF values. d The values of Ki
measured using IDIF corrected for spill-in with the late blood sample
are correlated with the Ki measured using IDIF corrected for spill-in
with the static phantom-derived function
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performed with 13C-acetate have shown that the average
uptake of acetate for the leg muscle at rest is 15 µmol min−1,
with a release rate of 5 µmol min−1, which accounts for 4%
and 1.5% of the available acetate, respectively [45]. These
results make it likely that enough 11C-acetate reaches the leg
muscle to correctly measure its perfusion index even at rest.
For the analysis of 18F-FTHA uptake in the femoral
muscle, we chose Patlak graphical analysis. Maki et al. [36]
did a 30-min heart acquisition followed by a 15-min
acquisition in the leg muscle. Plasma was collected
throughout the study and corrected for the presence of
metabolites. To obtain the IDIF in our study, we first
measured whole blood values from the images, corrected
them for PVE, then for the spill-in, for the presence of 18F-
FTHA metabolites and finally derived plasma values from
whole blood. Although the protocol for the femoral muscle
11C-acetate and brain 18F-FDG study did not require the
sampling of blood during the acquisition procedure, with
18F-FTHA, blood samples have to be collected for the
metabolites. The 18F-FTHA data were fitted to a one-phase
exponential decay to correct the IDIF. Nevertheless in the
long run, we aim to reduce or even completely eliminate the
need for blood sampling during 18F-FTHA acquisition.
However, since all of our data came from patients in whom
the circulating glucose level was kept constant with a
euglycaemic-hyperglycaemic clamp, further experiments
will have to be conducted in normal subjects before we
can presume universality of this method. We found that
uncorrected IDIF scores were inconsistent, but that correcting
for the recovery factor significantly reduced data variability
and yielded a good correlation (r2=0.78) between the results
calculated using the IDIF and actual AIF. These results
emphasize the importance of properly correcting IDIF before
using it for further analysis.
Data based on 18F-FDG standardized uptake value or
kinetic models are widely used in basic and clinical
research [1, 5, 8, 9]. When performing IDIF studies with
18F-FDG, the difference between concentrations of 18F-
FDG in whole blood and plasma can be ignored as it has
been shown to have little or no impact on the final results
[8]. Many studies have been conducted to eliminate the
need for serial blood sampling [4, 8, 9, 17] during image
acquisition, but most methods still require at least one
blood sample to calibrate the input curve with the blood
radioactivity concentration. Chen et al., for example, used a
combination of blood samples and independent component
analysis to obtain the input function [20]. Mourik et al.
found good agreement when using IDIF calibrated with a
blood sample, but had poorer results when using an IDIF
corrected with RCs, perhaps due to the method used to
measure the RC [22]. A similar approach was used by de
Geus-Oei et al. [46].
A major challenge in measuring IDIF is to obtain a
proper recovery factor for the reference artery. To assess the
robustness of our method for measuring arterial diameter,
we computed the impact of an error of ±1 mm on the IDIF
values. Even with a 1-mm deviation, the derived IDIF value
remained closer to the true AIF derived from blood
sampling as compared to an uncorrected IDIF value.
Fig. 6 CMRglc from standard three-compartment model analyses of
18F-FDG dynamic brain imaging, using an ROI on the frontal lobe of
the brain. a The K1 fit from the compartmental model was computed
using three different input functions: plasma sampling (Plasma), IDIF
without correction, and IDIF corrected for carotid artery PVE (IDIF
cor). b CMRglc was computed using three different input functions:
plasma sampling (Plasma), IDIF without correction, and IDIF
corrected for carotid artery partial volume (IDIF cor). For each
subject, the diameter of the carotid artery was obtained from the bolus
PET/CT coregistration images by measuring artery size on the CT
image. The data from each patient are identified by the same symbol
across all conditions. c Correlation between CMRglc of the frontal
brain region derived from plasma sampling and from IDIF corrected
for PVE
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Considering that we used the mean of six ROIs for the
femoral arteries, it is very unlikely that an error as large as
1 mm would have occurred; such an error exceeds our
experimental variability with the CT measurement which
was of the order of 0.5 mm for the carotid artery. With 18F-
FDG, PET/CT could be used to obtain the diameter of the
artery from the coregistered CT and 18F-FDG bolus PET
images. These images make it easy to correct the data for
PVE, an important advantage of this approach.
Conclusion
The use of PET/CT imaging with correction for spillover
and PVE allows precise determination of blood radiotracer
concentration in major vessels and makes it possible to
extract accurate quantitative kinetic data using an IDIF. As
a result, we showed that blood sampling can be avoided
during the acquisition while simultaneously obtaining a
precise and accurate AIF. The proposed method requires
precise phantom measurements of RCs and accurate
determination of artery diameter, which are procedures well
within the capability of most PET imaging facilities
involved in clinical research.
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